Spero Therapeutics (SPRO) stock rocketed on Wednesday after the clinical-stage biopharmaceutical company revealed results from a study conducted with GlaxoSmithKline (GSK). These results come from its Phase 3 PIVOT-PO trial of tebipenem HBr as an oral treatment for complicated urinary tract infections.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The big news here is the clinical trial will end early, as it has already met its primary endpoint. This was decided with the help of an Independent Data Monitoring Committee. GSK intends to include this data in a regulatory filing in the second half of 2025, which could clear the way for a commercial release.
SPRO stock surged 226.98% in pre-market trading on Wednesday. That rally will easily erase its year-to-date decline, as shares are being traded at $2.23, compared to $1.08 at the start of the year.
Is Spero Therapeutics Stock a Buy, Sell, or Hold?
Turning to Wall Street, only one analyst has covered Spero Therapeutics stock over the last three months. Four-star TD Cowen analyst Ritu Baral reiterated a Hold rating for SPRO shares earlier this month and didn’t provide a price target.
